MarginsXMarginsX
Home › Markets › Health Care › CRDF

Cardiff Oncology Inc. (CRDF)

CRDF trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$0.8477
+16.75% on the day
Market cap
$65.9M
Micro cap
Revenue · 2025
$593K
-13.2% on 2024
Net income · 2025
-$45.9M
-7732.0% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1213037/000119312526067464/0001193125-26-067464-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerCRDF on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0001213037
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inDE

Financials · 2025

LineValue
Revenue$593K
Net income-$45.9M
Operating income-$49.0M
Net margin-7732.0%
Operating margin-8256.3%
Revenue growth-13.2%
Cash$17.5M
Total assets$61.9M
P/E (computed)Net income was not positive
P/S (computed)111.2×

Warning signs

Cash runway
3.6 months
$12.1M cash at September 30, 2026
Share count, 1 year
+15.5%
2025-10-30 to 2026-11-03 · +74.1% over 3 years
Going-concern doubt
Yes
10-Q filed November 12, 2026
Insider net buying, 12 months
$1.1M
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"Management has performed an analysis and concluded that there exists a substantial doubt about the Company's ability to continue as a going concern."
10-Q 2026-11-12
Cash and burn$12.1M cash; operating cash flow -$10.0M a quarter.Report 2026-09-30
Shares outstanding77,795,249 (2026-11-03); 67,360,564 a year earlier; 44,677,169 three years earlier.Cover page 2026-11-03
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the marketLatest 2026-07-16
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorBDO USA, P.C., San Diego, California, United StatesPCAOB Form AP 2026-02-27
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $1.1M, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$171K-$8.9M-$9.9M$12.1MNo debt tags$559K10-Q 2026-11-12
Q2 2026
2026-06-30
$104K-$9.2M-$11.8M$9.2MNo debt tags$508K10-Q 2026-08-11
Q1 2026
2026-03-31
$41K-$12.3M-$12.3M$8.5MNo debt tags$525K10-Q 2026-05-14
Q4 2025
2025-12-31
$243K-$7.2M-$6.0M$17.5MNo debt tags$593K10-K 2026-02-24
Q3 2025
2025-09-30
$120K-$11.3M-$10.8M$10.1MNo debt tags$501K10-Q 2026-11-12
Q2 2025
2025-06-30
$121K-$13.9M-$8.3M$10.8MNo debt tags$546K10-Q 2026-08-11
Q1 2025
2025-03-31
$109K-$13.4M-$12.8M$24.1MNo debt tags$588K10-Q 2026-05-14
Q4 2024
2024-12-31
$151K-$11.8M-$10.3M$51.5MNo debt tags$684K10-K 2026-02-24

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-07-16
Latest annual report10-K2026-02-24
Latest quarterly / interim10-Q2026-11-12
Latest current report8-K2026-11-12
Latest proxyDEFA14A2026-08-26

Source: SEC EDGAR submissions feed, 1,004 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-8.8%
1 month-27.7%
3 months-25.5%
Year to date-74.0%
1 year-66.0%
From 52-week high-77.3%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
ATRAAtara Biotherapeutics Inc.$6.40-16.88%$65.2M
CSBRChampions Oncology Inc.$4.68-0.53%$65.1M
NMRANeumora Therapeutics Inc.$0.3695-13.85%$69.4M
OKYOOKYO Pharma Limited$1.18-12.96%$61.7M
CGTXCognition Therapeutics Inc.$0.6388-6.03%$60.8M
PMCBPharmaCyte Biotech Inc.$5.57-16.62%$59.8M
AVXLAnavex Life Sciences Corp.$0.8176-12.42%$75.8M
TNYATenaya Therapeutics Inc.$0.3336-4.47%$76.0M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier